Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Abigail Bogan

Physician Assistant, Medical Bossier City, LA Physician Assistant

NPI 1174304042 CMS profile 11551983

5341 Airline Dr, Bossier City, LA 71111

Open in the dashboard

General payments

$3,581

211 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Abigail Bogan of Bossier City, LA is reported in the CMS Open Payments database as having received $3,581 across 211 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,726 92
2024 General $1,729 112
2023 General $127 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abigail Bogan
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Abigail Bogan were reported at $1,726. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Abigail Bogan Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $0 $185 $55–$649 $149
2023 $127 $199 $58–$717 $160
2024 $1,729 $206 $62–$740 $164
2025 $1,726 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $742 55 payments
  2. Pfizer Inc. $620 39 payments
  3. Lilly USA, LLC $393 25 payments
  4. AstraZeneca Pharmaceuticals LP $353 19 payments
  5. Novo Nordisk Inc $276 19 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $267 14 payments
  7. Inspire Medical Systems, Inc. $184 2 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $128 7 payments
  9. Phathom Pharmaceuticals, Inc. $87 4 payments
  10. Amgen Inc. $84 4 payments
  11. Other $447 23 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,581 211 payments
Products named General payments · program years 2023–2025
  1. NURTEC ODT $558 36 payments
  2. QULIPTA $411 29 payments
  3. UBRELVY $405 28 payments
  4. ZAVZPRET $355 21 payments
  5. MOUNJARO $284 18 payments
  6. Kerendia $267 14 payments
  7. AIRSUPRA $259 14 payments
  8. Ozempic $206 13 payments
  9. ELIQUIS $203 15 payments
  10. VRAYLAR $188 14 payments
  11. Other $1,946 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

659

Median for Physician Assistant: 241

Drug cost

$117,151

Median for Physician Assistant: $4,110

Branded share of claims

22.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 39 $40,073
Mounjaro Tirzepatide Brand 24 $28,394
Januvia Sitagliptin Phosphate Brand 11 $13,242
Xarelto Rivaroxaban Brand 18 $11,008
Synjardy Xr Empagliflozin/Metformin Hcl Brand 12 $10,695
Entresto Sacubitril/Valsartan Brand 12 $8,121
Gabapentin Generic 28 $486
Cephalexin Generic 15 $449
Celecoxib Generic 18 $358
Losartan Potassium Generic 33 $355

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$15,115

Of which drugs: $97

Medicare patients

103

Average age 72

Services billed

451

55 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 43%
Ischemic heart disease 39%
Depression 24%
Chronic kidney disease 21%
COPD 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 13 52 $12
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 116 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $199
$199 24 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $158
$158 — —
VRAYLAR
  • AbbVie, Inc. $142
$142 — —
NURTEC ODT
  • PFIZER INC. $140
$140 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $130
$130 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

211 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record